Cargando…

Recombinant FSH Compared to Clomiphene Citrate as the First-Line in Ovulation Induction in Polycystic Ovary Syndrome Using Newly Designed Pens: A Randomized Controlled Trial

Objective: Since there is still controversy regarding the best first-line choice for ovulation induction (OI) other than clomiphene citrate (CC) in infertile women diagnosed with polycystic ovary syndrome (PCOS), the aim of the present study was to compare recombinant human FSH with CC as the first...

Descripción completa

Detalles Bibliográficos
Autores principales: Hossein-Rashidi, Batool, Khandzad, Bahareh, Shahrokh-Tehraninejad, Ensieh, Bagheri, Maryam, Gorginzadeh, Mansoureh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Tehran University of Medical Sciences 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4930453/
https://www.ncbi.nlm.nih.gov/pubmed/27385973
_version_ 1782440742480773120
author Hossein-Rashidi, Batool
Khandzad, Bahareh
Shahrokh-Tehraninejad, Ensieh
Bagheri, Maryam
Gorginzadeh, Mansoureh
author_facet Hossein-Rashidi, Batool
Khandzad, Bahareh
Shahrokh-Tehraninejad, Ensieh
Bagheri, Maryam
Gorginzadeh, Mansoureh
author_sort Hossein-Rashidi, Batool
collection PubMed
description Objective: Since there is still controversy regarding the best first-line choice for ovulation induction (OI) other than clomiphene citrate (CC) in infertile women diagnosed with polycystic ovary syndrome (PCOS), the aim of the present study was to compare recombinant human FSH with CC as the first course of OI in these women. Materials and methods: In this pilot randomized controlled trial, 104 infertile women diagnosed with PCOS were randomized in two groups to receive either CC with the dose of 100mg per day from day 3 of a spontaneous or progestin-induced menstruation for 5 days or rFSH with the starting dose of 50 IU daily {and weekly dose increment of as low as 12.5 IU}, on the day4 of the cycle. They were assessed during a single OI course. The pregnancy rate (PR) and live birth rate (LBR) were the primary outcomes. The follicular response, endometrial thickness, cancellation of the cycles and ovarian hyper stimulation (OHSS) rate were the secondary outcomes. Results: Analyzing data of 96 patients using Chi(2 )and Fischer’s Exact test (44 in rFSH group and 52 in CC group), both PR and LBR were comparable in the two groups {13.6% vs. 9.6% and 11.4% vs. 9.6% respectively}, with the difference not to be significant (p > 0.05). No cases of OHSS or multiple gestations happened during the treatment course. Conclusion: It seems that rFSH is as efficacious as CC while not with more complications for the first-line OI in infertile women with PCOS. However, due to the limitations of the present study including the small population and the single cycle of treatment, our results did not come out to prove this and more studies with larger study population are needed to compare the cumulative PR and LBR.
format Online
Article
Text
id pubmed-4930453
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Tehran University of Medical Sciences
record_format MEDLINE/PubMed
spelling pubmed-49304532016-07-06 Recombinant FSH Compared to Clomiphene Citrate as the First-Line in Ovulation Induction in Polycystic Ovary Syndrome Using Newly Designed Pens: A Randomized Controlled Trial Hossein-Rashidi, Batool Khandzad, Bahareh Shahrokh-Tehraninejad, Ensieh Bagheri, Maryam Gorginzadeh, Mansoureh J Family Reprod Health Original Article Objective: Since there is still controversy regarding the best first-line choice for ovulation induction (OI) other than clomiphene citrate (CC) in infertile women diagnosed with polycystic ovary syndrome (PCOS), the aim of the present study was to compare recombinant human FSH with CC as the first course of OI in these women. Materials and methods: In this pilot randomized controlled trial, 104 infertile women diagnosed with PCOS were randomized in two groups to receive either CC with the dose of 100mg per day from day 3 of a spontaneous or progestin-induced menstruation for 5 days or rFSH with the starting dose of 50 IU daily {and weekly dose increment of as low as 12.5 IU}, on the day4 of the cycle. They were assessed during a single OI course. The pregnancy rate (PR) and live birth rate (LBR) were the primary outcomes. The follicular response, endometrial thickness, cancellation of the cycles and ovarian hyper stimulation (OHSS) rate were the secondary outcomes. Results: Analyzing data of 96 patients using Chi(2 )and Fischer’s Exact test (44 in rFSH group and 52 in CC group), both PR and LBR were comparable in the two groups {13.6% vs. 9.6% and 11.4% vs. 9.6% respectively}, with the difference not to be significant (p > 0.05). No cases of OHSS or multiple gestations happened during the treatment course. Conclusion: It seems that rFSH is as efficacious as CC while not with more complications for the first-line OI in infertile women with PCOS. However, due to the limitations of the present study including the small population and the single cycle of treatment, our results did not come out to prove this and more studies with larger study population are needed to compare the cumulative PR and LBR. Tehran University of Medical Sciences 2016-03 /pmc/articles/PMC4930453/ /pubmed/27385973 Text en Copyright © Vali-e-Asr Reproductive Health Research Center, Tehran University of Medical Sciences This is an Open Access article distributed under the terms of the Creative Commons Attribution License, (http://creativecommons.org/licenses/by/3.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Hossein-Rashidi, Batool
Khandzad, Bahareh
Shahrokh-Tehraninejad, Ensieh
Bagheri, Maryam
Gorginzadeh, Mansoureh
Recombinant FSH Compared to Clomiphene Citrate as the First-Line in Ovulation Induction in Polycystic Ovary Syndrome Using Newly Designed Pens: A Randomized Controlled Trial
title Recombinant FSH Compared to Clomiphene Citrate as the First-Line in Ovulation Induction in Polycystic Ovary Syndrome Using Newly Designed Pens: A Randomized Controlled Trial
title_full Recombinant FSH Compared to Clomiphene Citrate as the First-Line in Ovulation Induction in Polycystic Ovary Syndrome Using Newly Designed Pens: A Randomized Controlled Trial
title_fullStr Recombinant FSH Compared to Clomiphene Citrate as the First-Line in Ovulation Induction in Polycystic Ovary Syndrome Using Newly Designed Pens: A Randomized Controlled Trial
title_full_unstemmed Recombinant FSH Compared to Clomiphene Citrate as the First-Line in Ovulation Induction in Polycystic Ovary Syndrome Using Newly Designed Pens: A Randomized Controlled Trial
title_short Recombinant FSH Compared to Clomiphene Citrate as the First-Line in Ovulation Induction in Polycystic Ovary Syndrome Using Newly Designed Pens: A Randomized Controlled Trial
title_sort recombinant fsh compared to clomiphene citrate as the first-line in ovulation induction in polycystic ovary syndrome using newly designed pens: a randomized controlled trial
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4930453/
https://www.ncbi.nlm.nih.gov/pubmed/27385973
work_keys_str_mv AT hosseinrashidibatool recombinantfshcomparedtoclomiphenecitrateasthefirstlineinovulationinductioninpolycysticovarysyndromeusingnewlydesignedpensarandomizedcontrolledtrial
AT khandzadbahareh recombinantfshcomparedtoclomiphenecitrateasthefirstlineinovulationinductioninpolycysticovarysyndromeusingnewlydesignedpensarandomizedcontrolledtrial
AT shahrokhtehraninejadensieh recombinantfshcomparedtoclomiphenecitrateasthefirstlineinovulationinductioninpolycysticovarysyndromeusingnewlydesignedpensarandomizedcontrolledtrial
AT bagherimaryam recombinantfshcomparedtoclomiphenecitrateasthefirstlineinovulationinductioninpolycysticovarysyndromeusingnewlydesignedpensarandomizedcontrolledtrial
AT gorginzadehmansoureh recombinantfshcomparedtoclomiphenecitrateasthefirstlineinovulationinductioninpolycysticovarysyndromeusingnewlydesignedpensarandomizedcontrolledtrial